Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026

Key Takeaway: SI-BONE, Inc. will report its financial results for Q4 and the full year of 2025 on February 23, 2026. The announcement includes details about a conference call for investors, which will take place at 1:30 p.m. PT. The company is recognized for its expertise in procedural solutions related to compromised bone.
Price reaction · baseline $16.37 (2026-02-02 close) · hit pre-market · clean, no other SIBN news in the window
day 0 close · peak
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is a leader in procedural solutions for compromised bone.
  • The company has a strong track record with over 140,000 procedures performed.
  • Management is actively engaging with investors through a conference call.

Full Press Release Details

SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link:https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the “Investors” section of the company’s website at:www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 200 peer reviewed publications.
For additional information on the company or the products, including risks and benefits, please visitwww.si-bone.com.
SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.

Frequently Asked Questions

When will SI-BONE report its financial results?

SI-BONE will report its financial results for Q4 and full year 2025 on February 23, 2026.

What time is the conference call for investors?

The conference call will begin at 1:30 p.m. Pacific Time on February 23, 2026.

How can investors access the conference call?

Investors can register for the conference call via a provided link or listen on the company's website.

What is SI-BONE known for?

SI-BONE is known for developing procedural solutions for clinical challenges related to compromised bone.

Last updated: Feb 3, 2026